Explore the Scientific R&D Platform

Try Now
Try Now

nQuery is now part of Dotmatics

April 27, 2022

Statsols is the company behind nQuery, and we are now proudly part of Dotmatics - the leader in R&D software that connects science, data, and decision-making. Please take a moment to read a statement from Dotmatics CEO Thomas Swalla below.

To our Statsols customers,

For more than 20 years, Statsols has worked with researchers and biostatisticians around the world to make clinical trials faster, less costly and more successful through our trial design platform nQuery. We help our clients save and improve patient lives by optimizing clinical research, making it as efficient and ethical as possible.

Today, I’m excited to share that we’re further advancing that vision by becoming part of Dotmatics. Read the press release here.


Dotmatics is the global leader in R&D scientific software combining an enterprise platform with best-of-breed applications you may already know - including Geneious, SnapGene and LabArchives - used by more than 2 million scientists around the world. We believe becoming part of Dotmatics is the best choice for Statsols and our customer community, because of our shared vision of advancing both clinical research and patient outcomes. With the power of Dotmatics behind us, we’ll be able to deliver new resources, expanded functionality and even better service to our customers. You’ll see direct benefits in the form of more personalized support, expanded workflow capabilities and faster innovation overall.

Statsols will remain the same platform you know and love. As we enter this next stage, we have the rare opportunity to continue providing industry-leading support for clinical trials, while making our services even more flexible, efficient and results-oriented than ever before.

From the team at Statsols, thank you for your ongoing support. Our customers have always been - and will continue to be - our highest priority. We look forward to continuing to sustain your life-changing clinical research.

Thomas Swalla

Subscribe by Email

No Comments Yet

Let us know what you think